Skip to main content Help with accessibility Skip to main navigation

Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, biological agents in the management of

CCG Approval Status:

Date Added: 31 - Jan - 2018
Body System:
Red

The Pan Mersey Area Prescribing Committee recommends the use of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumabâ–¼ in the management of ankylosing spondylitis (AS), and adalimumab, certolizumab pegol, golimumab and etanercept in non-radiographic axial spondyloarthritis (NRAxSpA) in accordance with NICE TA383, NICE TA407 and NICE TA497.

Prescribing pathway